Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Aug 1;15(8):a041315.
doi: 10.1101/cshperspect.a041315.

Ovarian Clear Cell Carcinoma: An Endometriosis-Associated Cancer with Therapeutic Challenges

Affiliations
Review

Ovarian Clear Cell Carcinoma: An Endometriosis-Associated Cancer with Therapeutic Challenges

Ruby Yun-Ju Huang et al. Cold Spring Harb Perspect Med. .

Abstract

Ovarian clear cell carcinoma (OCCC) is a histological subtype of epithelial ovarian cancer with distinct pathological features, molecular profiles, and biological functions. OCCC has high incidence rates in East Asia compared to the Western hemisphere and Europe and is associated with endometriosis. With its relative resistance to conventional treatment regimens and the worst stage-adjusted prognosis among ovarian cancer subtypes, there is an urgent need to optimize therapeutic options and to improve patient outcomes. To achieve this goal, better patient stratification strategies are required. These strategies could derive from comprehensive and in-depth multidimensional analysis of tumor heterogeneity. Understanding intertumor heterogeneity could assist us in stratifying OCCC patients based on features that are prognostic or predictive. Recent genomic, epigenomic, and transcriptomic profiling analyses allow us to provide an integrative perspective on the diverse heterogeneity in OCCC that could pave the way for novel translational research and clinical development in the future.

PubMed Disclaimer

References

    1. Anglesio MS, Carey MS, Köbel M, Mackay H, Huntsman DG. 2011. Clear cell carcinoma of the ovary: a report from the first ovarian clear cell symposium, June 24th, 2010. Gynecol Oncol 121: 407–415. 10.1016/j.ygyno.2011.01.005 - DOI - PubMed
    1. Anglesio MS, Papadopoulos N, Ayhan A, Nazeran TM, Noë M, Horlings HM, Lum A, Jones S, Senz J, Seckin T, et al. 2017. Cancer-associated mutations in endometriosis without cancer. N Engl J Med 376: 1835–1848. 10.1056/NEJMoa1614814 - DOI - PMC - PubMed
    1. Beddows I, Fan H, Heinze K, Johnson BK, Leonova A, Senz J, Djirackor S, Cho KR, Pearce CL, Huntsman DG, et al. 2024. Cell state of origin impacts development of distinct endometriosis-related ovarian carcinoma histotypes. Cancer Res 84: 26–38. 10.1158/0008-5472.CAN-23-1362 - DOI - PMC - PubMed
    1. Berek JS, Renz M, Kehoe S, Kumar L, Friedlander M. 2021. Cancer of the ovary, fallopian tube, and peritoneum: 2021 update. Int J Gynaecol Obstet 155(Suppl. 1): 61–85. 10.1002/ijgo.13878 - DOI - PMC - PubMed
    1. Bogani G, Ditto A, Lopez S, Bertolina F, Murgia F, Pinelli C, Chiappa V, Raspagliesi F. 2020. Adjuvant chemotherapy vs. observation in stage I clear cell ovarian carcinoma: a systematic review and meta-analysis. Gynecol Oncol 157: 293–298. 10.1016/j.ygyno.2019.12.045 - DOI - PubMed

MeSH terms

LinkOut - more resources